Lucid Capital initiated coverage of Aligos Therapeutics (ALGS) with a Buy rating and $36 price target The company’s lead asset, ALG-000184, is a potent small-molecule core assembly modulator in development for chronic hepatitis B, the analyst tells investors in a research note. The firm says that in Phase 1, ALG-000184 demonstrated potential best-in-class antiviral activity. It believes Aligos “represents a compelling opportunity at a very attractive entry point.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALGS:
- Promising Clinical Data and Strategic Milestones Drive Buy Rating for Aligos Therapeutics
- Aligos Therapeutics files to sell 6.25M shares of common stock for holders
- Aligos Therapeutics presents positive data at APASL2025
- Ten option delistings on March 24th
- Aligos Therapeutics announces inducement grants under Nasdaq listing rule